The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

OHSU one of 20 sites hosting the clinical trial for the amyloidosis therapy. Masri, who is overseeing the trial in Oregon, told The Lund Report that finding a way to deliver gene therapy directly to ...

The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...

BridgeBio Pharma Inc. gained US approval for a drug to treat a progressive and deadly form of heart disease, paving the way ...

Ultromics' EchoGo® Amyloidosis, clinical AI for echocardiography with the potential to revolutionize early detection of ...

A new type of therapy that ‘edits’ a gene in patients with a rare heart condition has been shown to be safe and effective, ...

A new type of therapy that 'edits' a gene in patients with a rare heart condition has been shown to be safe and effective, according to research from UCL and the Royal Free Hospital. Results for the ...

ATTR amyloidosis results from the buildup of transthyretin in the body. It can be inherited or acquired and can affect your heart, kidneys, and nervous system. While there’s no cure, treatment ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...